Recent Press Releases http://www.hyperiontx.com Hyperion, Inc. Hyperion Therapeutics Enrolls First Patient in Phase II Hepatic Encephalopathy Trial http://www.hyperiontx.com/press/release/pr_1259805691 Hyperion Therapeutics today announced that the first patient has been enrolled in its phase II clinical... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Announces First Patient Enrolled in Pivotal Trial in Patients with Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1256607501 Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics to Present at UBS 2009 Global Life Sciences Conference http://www.hyperiontx.com/press/release/pr_1253283700 Hyperion Therapeutics, Inc. today announced that Donald Santel, Chief Executive Officer, will present... Wed, 31 Dec 1969 16:33:29 -0800 HYPERION THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR HPN-100 FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY http://www.hyperiontx.com/press/release/pr_1253144476 Hyperion Therapeutics, Inc. today announced that its investigational product HPN-100 (glycerol phenylbutyrate)... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Announces First Patient Enrolled in Trial in Children with Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1252950110 Hyperion Therapeutics today announced that the first patient has been enrolled in a clinical trial... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Receives Special Protocol Assessment Approval from FDA for Pivotal Phase III Trial in Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1246940371 Hyperion Therapeutics today announced that it has reached agreement with the U.S. Food and Drug Administration... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Raises $60 Million Series C http://www.hyperiontx.com/press/release/pr_1246304166 Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Announces Results of Phase I Study in Patients with Liver Cirrhosis http://www.hyperiontx.com/press/release/pr_1243891161 Hyperion Therapeutics, Inc. today announced top-line results from a phase I study of HPN-100 in patients... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1241489052 Hyperion Therapeutics, Inc. today announced that HPN-100 has received orphan product designation from... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1238518388 Hyperion Therapeutics, Inc. today announced top-line results from their phase II study of HPN-100 for... Wed, 31 Dec 1969 16:33:29 -0800 Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting with FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1226428834 Hyperion Therapeutics, Inc. today reported completion of data analysis for its Phase 2 clinical trial... Wed, 31 Dec 1969 16:33:28 -0800 Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients with Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1216664468 Hyperion Therapeutics, Inc. today announced that it has completed patient enrollment in its Phase 1/2... Wed, 31 Dec 1969 16:33:28 -0800 Hyperion Therapeutics Names Bruce F. Scharschmidt CMO http://www.hyperiontx.com/press/release/pr_1209163723 Hyperion Therapeutics, Inc. today announced that it has named Bruce F. Scharschmidt, MD as Chief Medical... Wed, 31 Dec 1969 16:33:28 -0800 Hyperion Therapeutics Elects Lota Zoth to Board of Directors http://www.hyperiontx.com/press/release/pr_1207180840 Hyperion Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Lota S.... Wed, 31 Dec 1969 16:33:28 -0800 Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients with Hepatic Encephalopathy http://www.hyperiontx.com/press/release/pr_1203703379 Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in a Phase 2 clinical... Wed, 31 Dec 1969 16:33:28 -0800 Hyperion Therapeutics to Present at BIO CEO Investor Conference http://www.hyperiontx.com/press/release/pr_1202349171 Hyperion Therapeutics, Inc. today announced that the company is scheduled to present at the BIO CEO and... Wed, 31 Dec 1969 16:33:28 -0800 Hyperion Therapeutics, Inc. Names Mark Spring Senior Vice President and Chief Financial Officer http://www.hyperiontx.com/press/release/pr_1200678305 Hyperion Therapeutics, Inc. today announced the appointment of Mark Spring as Senior Vice President and... Wed, 31 Dec 1969 16:33:28 -0800 William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman http://www.hyperiontx.com/press/release/pr_1199493564 Hyperion Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development... Wed, 31 Dec 1969 16:33:28 -0800 Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients with Urea Cycle Disorders http://www.hyperiontx.com/press/release/pr_1193092819 Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in a Phase 1/2 clinical... Wed, 31 Dec 1969 16:33:27 -0800 Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event http://www.hyperiontx.com/press/release/pr_1191524267 Hyperion Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and... Wed, 31 Dec 1969 16:33:27 -0800 Hyperion Therapeutics Secures $40 Million in Series B Round http://www.hyperiontx.com/press/release/pr_1188930967 Hyperion Therapeutics, a biopharmaceutical company focused on the development and commercialization of... Wed, 31 Dec 1969 16:33:27 -0800 Medicis and Hyperion Therapeutics Announce Strategic Collaboration http://www.hyperiontx.com/press/release/pr_1188254706 Medicis (NYSE:MRX) and Hyperion Therapeutics, Inc. (“Hyperion”) today announced a strategic... Wed, 31 Dec 1969 16:33:27 -0800